Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Using mass spectrometry & NGF to analyze MRD negativity & long-term disease control in NDMM

Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, shares some insights into a study which evaluated the use of mass spectrometry and next-generation flow (NGF) to analyze measurable residual disease (MRD) and long-term disease control in patients with multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.